Achievements and obstacles of remyelinating therapies in multiple sclerosis

Achievements and obstacles of remyelinating therapies in multiple sclerosis, Published online: 17 November 2017; doi:10.1038/nrneurol.2017.139

NatureArticleSnippet(type=short-summary, markup=

Inadequate remyelination is central to degeneration and disability in patients with multiple sclerosis (MS); however, all currently approved therapies for MS are primarily immunomodulatory. Here, Martin Stangel and colleagues review our current knowledge of remyelination in MS, discuss results from clinical trials of remyelination-enhancing therapies, and evaluate the opportunities for future regenerative treatments.

, isJats=true)

中文翻译：

---

多发性硬化症中髓鞘再生疗法的成就和障碍

多发性硬化症中髓鞘再生疗法的成就和障碍

多发性硬化症中髓鞘再生疗法的成就和障碍，在线发布：2017年11月17日；doi：10.1038 / nrneurol.2017.139

NatureArticleSnippet（type = short-summary，markup =

髓鞘再生不足是多发性硬化症（MS）患者变性和残疾的关键。但是，目前所有批准的MS治疗方法主要是免疫调节的。在这里，Martin Stangel及其同事回顾了我们目前对MS髓鞘再生的知识，讨论了增强髓鞘再生疗法的临床试验结果，并评估了未来再生疗法的机会。

，isJats = true）